<p>Rani Therapeutics Holdings, Inc.（NASDAQ:RANI - 获取免费报告）的股票在周五的午盘交易中上涨了 1.3%。该股最高交易价格为 1.6650 美元，最后交易价格为 1.59 美元。在交易过程中，约有 2,328,448 股成交，较平均每日成交量 3,241,141 股下降了 28%。该股此前收盘价为 1.57 美元。</p>
<p>获取 <strong>Rani Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司对 RANI 进行了评论。Maxim Group 将 Rani Therapeutics 的目标价格从 5.00 美元上调至 10.00 美元，并在 10 月 20 日的研究报告中给予该股 “买入” 评级。Weiss Ratings 在周二的研究报告中重申了对 Rani Therapeutics 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 21 日的研究报告中重新发布了 “买入” 评级，并对 Rani Therapeutics 股票设定了 11.00 美元的价格目标。最后，Wall Street Zen 在 8 月 16 日的研究报告中将 Rani Therapeutics 的股票评级从 “卖出” 上调至 “持有”。四位研究分析师给予该股 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均价格目标为 8.50 美元。</p>
<p><strong>获取我们关于 Rani Therapeutics 的最新报告</strong></p>
<h2>Rani Therapeutics 股票表现</h2>
<p>该公司的市值为 1.932 亿美金，市盈率为-2.01，贝塔值为 0.40。该股的 50 日简单移动平均为 1.49 美元，200 日简单移动平均为 0.87 美元。</p>
<p>Rani Therapeutics（NASDAQ:RANI - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告每股收益为（0.12 美元），低于分析师的共识预期（0.09 美元）3 美分。平均而言，股票分析师预计 Rani Therapeutics Holdings, Inc.在本年度将发布-1.01 的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，主要股东 South Cone Investments Limited 于 10 月 21 日出售了 400 万股该公司的股票。该股票以平均价格 2.77 美元出售，总交易额为 11,080,000.00 美元。出售后，内部人士在公司中持有 2,379,194 股，价值 6,590,367.38 美元。此交易代表其持股比例减少了 62.70%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，董事 Mir A. Imran 于 10 月 23 日的交易中购买了 2,083,334 股 Rani Therapeutics 股票。这些股票以每股 0.60 美元的平均价格收购，总交易额为 1,250,000.40 美元。交易完成后，该董事直接持有 2,083,334 股公司股票，价值 1,250,000.40 美元。此交易代表其持股比例的∞增长。该购买的 SEC 文件提供了更多信息。公司内部人士持有公司 45.08% 的股票。</p>
<h2>机构投资者对 Rani Therapeutics 的看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对该公司的投资。King Luther Capital Management Corp 在第一季度将其在 Rani Therapeutics 的持股增加了 75.8%。King Luther Capital Management Corp 现在拥有 58,000 股该公司的股票，价值 73,000 美元，此前在该期间内又购买了 25,000 股。Janney Montgomery Scott LLC 在第二季度将其在 Rani Therapeutics 的持股增加了 102.9%。Janney Montgomery Scott LLC 现在拥有 55,200 股该公司的股票，价值 28,000 美元，此前在该期间内又购买了 28,000 股。Well Done LLC 在第二季度获得了 Rani Therapeutics 的新头寸，价值约 27,000 美元。CWA Asset Management Group LLC 在第三季度将其在 Rani Therapeutics 的持股增加了 80.0%。CWA Asset Management Group LLC 现在拥有 150,000 股该公司的股票，价值 75,000 美元，此前在该期间内又购买了 66,667 股。最后，Kestra Private Wealth Services LLC 在第三季度将其在 Rani Therapeutics 的持股增加了 44.8%。Kestra Private Wealth Services LLC 现在拥有 226,142 股该公司的股票，价值 113,000 美元，此前在该期间内又购买了 70,002 股。目前，30.19% 的股票由机构投资者和对冲基金持有。</p>
<h2>Rani Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Rani Therapeutics Holdings, Inc.是一家临床阶段的生物治疗公司，开发口服给药的生物制剂，服务于美国的患者、医生和医疗系统。该公司开发了 RaniPill 胶囊，这是一种药物无关的口服给药平台，用于传递多种药物成分，包括寡核苷酸、肽、蛋白质和抗体。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票比 Rani Therapeutics 更好</li>
<li>哪里可以找到财报电话会议记录</li>
<li>Rocket Lab 的大反弹？分析师建议此次下跌是个机会</li>
<li>高股息 REIT：它们是理想的多元化方式吗？</li>
<li>Meta 的 AI 时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>恒生指数是什么？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Rani Therapeutics 吗？</h2>
<p>在考虑 Rani Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rani Therapeutics 并不在名单上。</p>
<p>虽然 Rani Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RANI

<p>Rani Therapeutics 的股票上涨了 1.3%，但交易量有所下降。分析师的评级不一，Maxim Group 将目标价上调至 10 美元，而 HC Wainwright 则设定为 11 美元。内部交易方面，一位主要股东出售了 400 万股，而一位董事购买了超过 200 万股。机构投资者已调整其持股，有些显著增加了持股比例。该公司专注于口服生物制剂的递送，市值为 1.932 亿美元，市盈率为-2.01</p>

<p>Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) rose 1.3% during mid-day trading on Friday . The stock traded as high as $1.6650 and last traded at $1.59. Approximately 2,328,448 shares traded hands during trading, a decline of 28% from the average daily volume of 3,241,141 shares. The stock had previously closed at $1.57.</p>
<div class="lb-trans"><p>Rani Therapeutics Holdings, Inc.（NASDAQ:RANI - 获取免费报告）的股票在周五的午盘交易中上涨了 1.3%。该股最高交易价格为 1.6650 美元，最后交易价格为 1.59 美元。在交易过程中，约有 2,328,448 股成交，较平均每日成交量 3,241,141 股下降了 28%。该股此前收盘价为 1.57 美元。</p>
</div><p>Get <strong>Rani Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rani Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have commented on RANI. Maxim Group boosted their target price on Rani Therapeutics from $5.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, October 20th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Rani Therapeutics in a research note on Tuesday. HC Wainwright reissued a &#34;buy&#34; rating and issued a $11.00 price objective on shares of Rani Therapeutics in a research note on Tuesday, October 21st. Finally, Wall Street Zen upgraded shares of Rani Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.50.</p>
<div class="lb-trans"><p>多家研究公司对 RANI 进行了评论。Maxim Group 将 Rani Therapeutics 的目标价格从 5.00 美元上调至 10.00 美元，并在 10 月 20 日的研究报告中给予该股 “买入” 评级。Weiss Ratings 在周二的研究报告中重申了对 Rani Therapeutics 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 21 日的研究报告中重新发布了 “买入” 评级，并对 Rani Therapeutics 股票设定了 11.00 美元的价格目标。最后，Wall Street Zen 在 8 月 16 日的研究报告中将 Rani Therapeutics 的股票评级从 “卖出” 上调至 “持有”。四位研究分析师给予该股 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均价格目标为 8.50 美元。</p>
</div><p><strong>Get Our Latest Report on Rani Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Rani Therapeutics 的最新报告</strong></p>
</div><h2>Rani Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Rani Therapeutics 股票表现</h2>
</div><p>The company has a market capitalization of $193.20 million, a PE ratio of -2.01 and a beta of 0.40. The stock's fifty day simple moving average is $1.49 and its 200-day simple moving average is $0.87.</p>
<div class="lb-trans"><p>该公司的市值为 1.932 亿美金，市盈率为-2.01，贝塔值为 0.40。该股的 50 日简单移动平均为 1.49 美元，200 日简单移动平均为 0.87 美元。</p>
</div><p>Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.03). On average, equities analysts anticipate that Rani Therapeutics Holdings, Inc. will post -1.01 EPS for the current year.</p>
<div class="lb-trans"><p>Rani Therapeutics（NASDAQ:RANI - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告每股收益为（0.12 美元），低于分析师的共识预期（0.09 美元）3 美分。平均而言，股票分析师预计 Rani Therapeutics Holdings, Inc.在本年度将发布-1.01 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, major shareholder South Cone Investments Limited sold 4,000,000 shares of the firm's stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the sale, the insider owned 2,379,194 shares in the company, valued at $6,590,367.38. This trade represents a 62.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, Director Mir A. Imran bought 2,083,334 shares of Rani Therapeutics stock in a transaction that occurred on Thursday, October 23rd. The shares were acquired at an average price of $0.60 per share, for a total transaction of $1,250,000.40. Following the completion of the transaction, the director directly owned 2,083,334 shares of the company's stock, valued at $1,250,000.40. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 45.08% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，主要股东 South Cone Investments Limited 于 10 月 21 日出售了 400 万股该公司的股票。该股票以平均价格 2.77 美元出售，总交易额为 11,080,000.00 美元。出售后，内部人士在公司中持有 2,379,194 股，价值 6,590,367.38 美元。此交易代表其持股比例减少了 62.70%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，董事 Mir A. Imran 于 10 月 23 日的交易中购买了 2,083,334 股 Rani Therapeutics 股票。这些股票以每股 0.60 美元的平均价格收购，总交易额为 1,250,000.40 美元。交易完成后，该董事直接持有 2,083,334 股公司股票，价值 1,250,000.40 美元。此交易代表其持股比例的∞增长。该购买的 SEC 文件提供了更多信息。公司内部人士持有公司 45.08% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Rani Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Rani Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. King Luther Capital Management Corp raised its holdings in shares of Rani Therapeutics by 75.8% in the 1st quarter. King Luther Capital Management Corp now owns 58,000 shares of the company's stock worth $73,000 after purchasing an additional 25,000 shares during the period. Janney Montgomery Scott LLC raised its holdings in Rani Therapeutics by 102.9% in the second quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company's stock valued at $28,000 after buying an additional 28,000 shares during the period. Well Done LLC acquired a new position in Rani Therapeutics during the second quarter valued at approximately $27,000. CWA Asset Management Group LLC grew its stake in Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company's stock worth $75,000 after buying an additional 66,667 shares during the period. Finally, Kestra Private Wealth Services LLC grew its stake in Rani Therapeutics by 44.8% during the third quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company's stock worth $113,000 after buying an additional 70,002 shares during the period. 30.19% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对该公司的投资。King Luther Capital Management Corp 在第一季度将其在 Rani Therapeutics 的持股增加了 75.8%。King Luther Capital Management Corp 现在拥有 58,000 股该公司的股票，价值 73,000 美元，此前在该期间内又购买了 25,000 股。Janney Montgomery Scott LLC 在第二季度将其在 Rani Therapeutics 的持股增加了 102.9%。Janney Montgomery Scott LLC 现在拥有 55,200 股该公司的股票，价值 28,000 美元，此前在该期间内又购买了 28,000 股。Well Done LLC 在第二季度获得了 Rani Therapeutics 的新头寸，价值约 27,000 美元。CWA Asset Management Group LLC 在第三季度将其在 Rani Therapeutics 的持股增加了 80.0%。CWA Asset Management Group LLC 现在拥有 150,000 股该公司的股票，价值 75,000 美元，此前在该期间内又购买了 66,667 股。最后，Kestra Private Wealth Services LLC 在第三季度将其在 Rani Therapeutics 的持股增加了 44.8%。Kestra Private Wealth Services LLC 现在拥有 226,142 股该公司的股票，价值 113,000 美元，此前在该期间内又购买了 70,002 股。目前，30.19% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Rani Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Rani Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.</p>
<div class="lb-trans"><p>Rani Therapeutics Holdings, Inc.是一家临床阶段的生物治疗公司，开发口服给药的生物制剂，服务于美国的患者、医生和医疗系统。该公司开发了 RaniPill 胶囊，这是一种药物无关的口服给药平台，用于传递多种药物成分，包括寡核苷酸、肽、蛋白质和抗体。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Rani Therapeutics</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>What is the Hang Seng index?</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Rani Therapeutics 更好</li>
<li>哪里可以找到财报电话会议记录</li>
<li>Rocket Lab 的大反弹？分析师建议此次下跌是个机会</li>
<li>高股息 REIT：它们是理想的多元化方式吗？</li>
<li>Meta 的 AI 时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>恒生指数是什么？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rani Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rani Therapeutics 吗？</h2>
</div><p>Before you consider Rani Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rani Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rani Therapeutics 并不在名单上。</p>
</div><p>While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rani Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rani Therapeutics（NASDAQ:RANI）股价上涨 1.3% - 以下是原因